AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7877288 — intervention group
Group type: COMPARATOR
Intervention: Equivalent exposure to intervals without feedback
Number of subjects: 30
Study 3041354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandoglobulin (immunoglobulin prepared for intravenous administration)
Number of subjects: 0
Study 3041354 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Sandoglobulin
Number of subjects: 0
Study 3041354 — intervention group
Group type: COMPARATOR
Intervention: Parenteral albumin
Number of subjects: 0
Study 28914720 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic corrective exercise program (1 hour/session, twice per week for 8 weeks, total of 16 sessions)
Number of subjects: 50
Study 28914720 — intervention group
Group type: COMPARATOR
Intervention: Education on thoracic corrective exercise program and a booklet of exercises (Control Group)
Number of subjects: 50
Study 28914720 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic corrective exercise program
Number of subjects: 50
Study 30541093 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WGW) 98 g/d
Number of subjects: 50
Study 30541093 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat (RW) 98 g/d
Number of subjects: 50
Study 28394951 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthful dietary pattern (consumption of fruits, vegetables, legumes, bread, rusk, and pasta)
Number of subjects: 1485
Study 28394951 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for carbohydrate percentage
Number of subjects: 1485
Study 24484688 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous hydration (up to 1.5 l/day for 72 hours)
Number of subjects: 67
Study 24484688 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration (up to 1.5 l/day for 72 hours)
Number of subjects: 67
Study 24484688 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous hydration
Number of subjects: 67
Study 22233189 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-dose naltrexone (VLNTX) 0.125 or 0.25 mg/day
Number of subjects: 127
Study 22233189 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-dose naltrexone (VLNTX) + clonidine (0.1-0.2 mg q6h)
Number of subjects: 127
Study 22233189 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.1-0.2 mg q6h)
Number of subjects: 127
Study 22233189 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone placebo
Number of subjects: 127
Study 21054829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (counselling on daily physical activity, physical fitness training, sports advice)
Number of subjects: 60
Study 21054829 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment; current policy)
Number of subjects: 60
Study 17391155 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% aminophylline cream applied to the waist twice a day
Number of subjects: 50
Study 17391155 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control) applied to the waist
Number of subjects: 50
Study 15766477 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaiku's Benecol containing 2 g/bottle of plant stanol esters
Number of subjects: 32
Study 15766477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same product without plant stanol)
Number of subjects: 32
Study 12018956 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (prophylactic treatment)
Number of subjects: 37
Study 12018956 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated after first seizure)
Number of subjects: 37
Study 9831406 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (bismuth subnitrate 3 x 375 mg for 4 weeks + tetracycline 3 x 500 mg + metronidazole 3 x 250 mg daily for 2 weeks)
Number of subjects: 101
Study 9831406 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (amoxicillin 2 x 1000 mg + omeprazole 2 x 20 mg daily for 2 weeks)
Number of subjects: 101
Study 7798414 — intervention group
Group type: EXPERIMENTAL
Intervention: Acral lentiginous melanoma (ALM)
Number of subjects: 165
Study 7798414 — intervention group
Group type: COMPARATOR
Intervention: Acral (nonlentiginous) melanoma
Number of subjects: 165
Study 3190971 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg and atropine 1.2 mg
Number of subjects: 38
Study 3190971 — intervention group
Group type: COMPARATOR
Intervention: No drugs to facilitate antagonism of blockade (Control)
Number of subjects: 38
Study 5293942 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinaldix
Number of subjects: 17
Study 7435720 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient clerkship
Number of subjects: 80
Study 7435720 — intervention group
Group type: COMPARATOR
Intervention: Inpatient psychiatry
Number of subjects: 80
Study 31311509 — intervention group
Group type: EXPERIMENTAL
Intervention: Free healthy school meal served every school day for one year
Number of subjects: 164
Study 28389799 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO2 levels 36‐40 mmHg (Group 1)
Number of subjects: 400
Study 28389799 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO2 levels 41‐45 mmHg (Group 2)
Number of subjects: 400
Study 28389799 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO2 levels 46‐50 mmHg (Group 3)
Number of subjects: 400
Study 25888838 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mother-Infant Transaction Program (8 one-hour sessions + 4 home visits)
Number of subjects: 221
Study 25888838 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mother-Infant Transaction Program
Number of subjects: 221
Study 25888838 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care according to hospital guidelines)
Number of subjects: 221
Study 23711332 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct information about reflex areas (eye reflex area at the base of the second toe)
Number of subjects: 32
Study 23711332 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-information about reflex areas (shoulder reflex area at the base of the third toe)
Number of subjects: 32
Study 21272067 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (PTx)
Number of subjects: 1972
Study 21272067 — intervention group
Group type: COMPARATOR
Intervention: No Phototherapy (NoPTx)
Number of subjects: 1972
Study 20509517 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional intraoperative aerostasis with 100% autologous fibrin glue (AFG)
Number of subjects: 100
Study 20509517 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 100
Study 17541328 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 77
Study 17541328 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 77
Study 15480592 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual motor execution
Number of subjects: 0
Study 15480592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental motor imagery
Number of subjects: 0
Study 15480592 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation period of motor acts
Number of subjects: 0
Study 11247549 — intervention group
Group type: EXPERIMENTAL
Intervention: DOTS with direct observation of treatment by health workers
Number of subjects: 497
Study 11247549 — intervention group
Group type: EXPERIMENTAL
Intervention: DOTS with direct observation of treatment by family members
Number of subjects: 497
Study 11247549 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered treatment
Number of subjects: 497
Study 9661989 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress session for all groups except for restrainers who smoked ad lib.
Number of subjects: 48
Study 9661989 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-abstinent restrainers during the stress session
Number of subjects: 48
Study 9661989 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrainers
Number of subjects: 48
Study 9661989 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 48
Study 9661989 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake
Number of subjects: 48
Study 7876505 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mesalamine (Asacol) 3.2 g/day
Number of subjects: 38
Study 7876505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3284724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (2 gm, intravenously, three times on the day of surgery)
Number of subjects: 100
Study 3284724 — intervention group
Group type: COMPARATOR
Intervention: Penicillin and streptomycin (penicillin, 2 ml, IU, intramuscularly, three times daily for six days; streptomycin, 0.5 gm, intramuscularly, two times daily for four days)
Number of subjects: 100
Study 31180763 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme with monthly reinforcement sessions
Number of subjects: 160
Study 31180763 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 160
Study 28625567 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 28
Study 28625567 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS (Control)
Number of subjects: 28
Study 25927495 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT) program
Number of subjects: 160
Study 25927495 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 160
Study 23734126 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive working memory training scheme
Number of subjects: 36
Study 23734126 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive version of the program (Control)
Number of subjects: 36
Study 22198602 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69ST membrane
Number of subjects: 54
Study 22198602 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone F60 membrane
Number of subjects: 54
Study 19812871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramiprosate 100 mg
Number of subjects: 1052
Study 19812871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramiprosate 150 mg
Number of subjects: 1052
Study 19812871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052
Study 16508926 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) alone
Number of subjects: 0
Study 16508926 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) plus infliximab
Number of subjects: 0
Study 14529954 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg lamotrigine (LTG) as a single dose
Number of subjects: 16
Study 14529954 — intervention group
Group type: EXPERIMENTAL
Intervention: bi-hourly graded cumulative dose of lamotrigine (LTG)
Number of subjects: 16
Study 14529954 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 10716041 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 8
Study 10716041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide 500 mg
Number of subjects: 8
Study 10716041 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 8
Study 9420845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1 mL/kg 95% ethanol)
Number of subjects: 7
Study 9420845 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate punch (isocaloric)
Number of subjects: 7
Study 2020905 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment (AC group)
Number of subjects: 188
Study 2020905 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant treatment (O group)
Number of subjects: 188
Study 7039927 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg for 2 doses, orally, 24 hours apart)
Number of subjects: 47
Study 7039927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 7039927 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 47
Study 29749112 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-enhanced writing therapy (12 hours)
Number of subjects: 21
Study 29749112 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist, no therapy for 6 weeks)
Number of subjects: 21
Study 29465679 — intervention group
Group type: EXPERIMENTAL
Intervention: Data to Care intervention (medical provider contact, patient contact, structured individual interview)
Number of subjects: 822
Study 29465679 — intervention group
Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 822
Study 26892695 — intervention group
Group type: EXPERIMENTAL
Intervention: 200μg sublingual misoprostol
Number of subjects: 124
Study 26892695 — intervention group
Group type: EXPERIMENTAL
Intervention: 400μg sublingual misoprostol
Number of subjects: 124
Study 26892695 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 200μg vs 400μg
Number of subjects: 124
Study 24156566 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 50 μg o.d.
Number of subjects: 1888
Study 24156566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1888
Study 24156566 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg o.d.
Number of subjects: 1888
Study 22414198 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led self-management coaching intervention (three home visits by an expert patient)
Number of subjects: 133
Study 22414198 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led self-management coaching intervention
Number of subjects: 133
Study 22414198 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 133
Study 20155327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment (n = 255)
Number of subjects: 498
Study 20155327 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment according to Dutch guidelines (n = 243)
Number of subjects: 498
Study 18089478 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (fix combination of 4/1.25 mg perindopril/indapamide)
Number of subjects: 861
Study 18089478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 861
Study 16002812 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula
Number of subjects: 168
Study 16002812 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula
Number of subjects: 168
Study 16002812 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 168
Study 12421054 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous and exogenous saccades programmed in a common saccade map.
Number of subjects: 0
Study 12421054 — intervention group
Group type: EXPERIMENTAL
Intervention: Top‐down, location‐specific inhibition of locations to which the saccade should not go.
Number of subjects: 0
Study 10338459 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg BID
Number of subjects: 83
Study 10338459 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg BID
Number of subjects: 83
Study 10338459 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 83
Study 7489145 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (250 micrograms/m2/day)
Number of subjects: 34
Study 7489145 — intervention group
Group type: COMPARATOR
Intervention: rhG‐CSF (10 micrograms/kg/day)
Number of subjects: 34
Study 1658183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1658183 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 10 mg daily
Number of subjects: 12
Study 1658183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril and physical training
Number of subjects: 12
Study 1658183 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training alone
Number of subjects: 12
Study 7148456 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 23
Study 7148456 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 23
Study 31813170 — intervention group
Group type: EXPERIMENTAL
Intervention: Blondes (VAS for fun sitting upright)
Number of subjects: 21
Study 31813170 — intervention group
Group type: COMPARATOR
Intervention: Non-blondes (VAS for fun sitting upright)
Number of subjects: 21
Study 31813170 — intervention group
Group type: EXPERIMENTAL
Intervention: Blondes (VAS for fun lying down)
Number of subjects: 21
Study 31813170 — intervention group
Group type: COMPARATOR
Intervention: Non-blondes (VAS for fun lying down)
Number of subjects: 21
Study 31813170 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterslide lying down (VAS for fun)
Number of subjects: 21
Study 31813170 — intervention group
Group type: COMPARATOR
Intervention: Waterslide sitting upright (VAS for fun)
Number of subjects: 21
Study 31813170 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterslide lying down (duration)
Number of subjects: 21
Study 31813170 — intervention group
Group type: COMPARATOR
Intervention: Waterslide sitting upright (duration)
Number of subjects: 21
Study 28562099 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 1% (androgel) before Controlled Ovarian Stimulation (COS)
Number of subjects: 110
Study 28562099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no testosterone gel)
Number of subjects: 110
Study 26801905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/tramadol 25 mg/75 mg
Number of subjects: 606
Study 26801905 — intervention group
Group type: COMPARATOR
Intervention: Dexketoprofen 25 mg
Number of subjects: 606
Study 26801905 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 100 mg
Number of subjects: 606
Study 26801905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 25412338 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (15 g bd) + sitagliptin (100 mg/d)
Number of subjects: 13
Study 25412338 — intervention group
Group type: COMPARATOR
Intervention: Glutamine (15 g bd) + placebo
Number of subjects: 13
Study 23005589 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal emotional self-management training program
Number of subjects: 240
Study 23005589 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study 19833616 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT1
Number of subjects: 350
Study 19833616 — intervention group
Group type: EXPERIMENTAL
Intervention: OPA1
Number of subjects: 350
Study 19833616 — intervention group
Group type: COMPARATOR
Intervention: DCT2
Number of subjects: 350
Study 17722962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus once-daily (OD)
Number of subjects: 0
Study 17722962 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard tacrolimus (twice daily)
Number of subjects: 0
Study 17722962 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin microemulsion
Number of subjects: 0
Study 17722962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus OD
Number of subjects: 0
Study 16221103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (IVC) 0.75-1 g/m² monthly for 6 months
Number of subjects: 44
Study 16221103 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2 g/day for 6 months
Number of subjects: 44
Study 16221103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IVC and MMF)
Number of subjects: 44
Study 16221103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (IVC)
Number of subjects: 44
Study 12364686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE)
Number of subjects: 37
Study 10193958 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent UltraPulse
Number of subjects: 7
Study 10193958 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Technologies TruPulse
Number of subjects: 7
Study 10193958 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharplan FeatherTouch
Number of subjects: 7
Study 10193958 — intervention group
Group type: EXPERIMENTAL
Intervention: Luxar NovaPulse
Number of subjects: 7
Study 1579769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier
Number of subjects: 42
Study 1579769 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 42
Study 2990196 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 M NaHCO3
Number of subjects: 14
Study 2990196 — intervention group
Group type: COMPARATOR
Intervention: 0.4 M NaCl
Number of subjects: 14
Study 2990196 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of liquid antacid (aluminum and magnesium hydroxide)
Number of subjects: 14
Study 2990196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied)
Number of subjects: 14
Study 30903117 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal implants
Number of subjects: 27
Study 30903117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-screws
Number of subjects: 27
Study 30903117 — intervention group
Group type: COMPARATOR
Intervention: Palatal implants or mini-screws
Number of subjects: 27
Study 30020886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud pack to eyes
Number of subjects: 60
Study 30020886 — intervention group
Group type: COMPARATOR
Intervention: Wet pack to eyes
Number of subjects: 60
Study 27501056 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital palpation of the pilot balloon
Number of subjects: 180
Study 27501056 — intervention group
Group type: COMPARATOR
Intervention: Continuous manometry
Number of subjects: 180
Study 26416195 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided starting position (RL)
Number of subjects: 163
Study 26416195 — intervention group
Group type: COMPARATOR
Intervention: Left-sided starting position (LL)
Number of subjects: 163
Study 24151591 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (cyclobenzaprine tablet)
Number of subjects: 23
Study 24151591 — intervention group
Group type: COMPARATOR
Intervention: Reference product (cyclobenzaprine tablet)
Number of subjects: 23
Study 24151591 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference products
Number of subjects: 23
Study 21127191 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes closed comfortable stance condition
Number of subjects: 150
Study 21127191 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including medial-lateral sway velocity, anterior-posterior short-term α-scaling exponent, medial-lateral short-term α-scaling exponent, mean frequency, body mass index, and age
Number of subjects: 150